Cue Biopharma, Inc. (CUE)
27.66
+5.33
(+23.87%)
USD |
NASDAQ |
Oct 09, 16:00
27.87
+0.21
(+0.76%)
After-Hours: 20:00
Cue Biopharma Enterprise Value : 136.06M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 136.06M |
| October 08, 2026 | 108.19M |
| October 07, 2026 | 109.13M |
| October 06, 2026 | 112.42M |
| October 05, 2026 | 118.80M |
| October 02, 2026 | 125.13M |
| October 01, 2026 | 123.46M |
| September 30, 2026 | 126.70M |
| September 29, 2026 | 124.82M |
| September 28, 2026 | 134.96M |
| September 25, 2026 | 155.67M |
| September 24, 2026 | 163.20M |
| September 23, 2026 | 157.24M |
| September 22, 2026 | 153.00M |
| September 21, 2026 | 139.25M |
| September 18, 2026 | 185.16M |
| September 17, 2026 | 189.30M |
| September 16, 2026 | 170.10M |
| September 15, 2026 | 156.87M |
| September 14, 2026 | 151.17M |
| September 11, 2026 | 141.71M |
| September 10, 2026 | 137.84M |
| September 09, 2026 | 150.91M |
| September 08, 2026 | 148.30M |
| September 04, 2026 | 134.91M |
| Date | Value |
|---|---|
| September 03, 2026 | 136.11M |
| September 02, 2026 | 132.40M |
| September 01, 2026 | 140.14M |
| August 31, 2026 | 124.87M |
| August 28, 2026 | 137.21M |
| August 27, 2026 | 138.67M |
| August 26, 2026 | 142.28M |
| August 25, 2026 | 131.35M |
| August 24, 2026 | 112.63M |
| August 21, 2026 | 116.82M |
| August 20, 2026 | 120.11M |
| August 19, 2026 | 128.84M |
| August 18, 2026 | 125.81M |
| August 17, 2026 | 135.96M |
| August 14, 2026 | 170.26M |
| August 13, 2026 | 153.94M |
| August 12, 2026 | 150.49M |
| August 11, 2026 | 139.09M |
| August 10, 2026 | 127.90M |
| August 07, 2026 | 133.24M |
| August 06, 2026 | 132.66M |
| August 05, 2026 | 130.78M |
| August 04, 2026 | 130.52M |
| August 03, 2026 | 131.93M |
| July 31, 2026 | 131.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xilio Therapeutics, Inc. | -70.19M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -153.07M |
| Revenue (Quarterly) | 7.877M |
| Total Expenses (Quarterly) | 160.94M |
| EPS Diluted (Quarterly) | -24.14 |
| Gross Profit Margin (Quarterly) | 99.54% |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -97.62% |
| Normalized Earnings Yield | -107.40 |